Clinical Trial

Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a phase II trial of T cell receptor alpha/beta depletion (α/β TCD) peripheral blood stem cell (PBSC) transplantation in patients with inherited bone marrow failure (BMF) disorders to eliminate the need for routine graft-versus-host disease (GVHD) immune suppression leading to earlier immune recovery and potentially a reduction in the risk of severe infections after transplantation.
Protocol Amendment History 13 amendments
This ClinicalTrials.gov record has been amended 13 times since 2018-07-06; most recent amendment 2026-01-29.
Status change: Withheld → Recruiting 2018-11-26
Trial Details
NCT Number NCT03579875
Lead Sponsor Masonic Cancer Center, University of Minnesota
Conditions Fanconi Anemia, Severe Aplastic Anemia, Myelodysplastic Syndromes, T Cell Receptor Alpha/Beta Depletion, Telomere Biology Disorder, Bone Marrow Failure, Dyskeratosis Congenita, Telomere Biology Disorders
Enrollment 48 participants
Start Date 2018-11-13
Primary Completion 2027-01-01 (estimated)
Study Completion 2029-01-05 (estimated)
Updated on ClinicalTrials.gov 2026-01-30